专家论坛

心血管转化研究的若干进展

展开
  • 上海交通大学医学院附属瑞金医院心内科 上海交通大学医学院心血管病研究所,上海 200025

收稿日期: 2022-09-05

  网络出版日期: 2022-11-04

Several advances of translational research in cardiovascular diseases

Expand

Received date: 2022-09-05

  Online published: 2022-11-04

本文引用格式

陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰 . 心血管转化研究的若干进展[J]. 内科理论与实践, 2022 , 17(05) : 369 -372 . DOI: 10.16138/j.1673-6087.2022.05.004

参考文献

[1] Lam MP, Ping P, Murphy E. Proteomics research in cardiovascular medicine and biomarker discovery[J]. J Am Coll Cardiol, 2016, 68(25): 2819-2830.
[2] Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2): 625-643.
[3] Kullo IJ, Cooper LT. Early identification of cardiovascular risk using genomics and proteomics[J]. Nat Rev Cardiol, 2010, 7(6): 309-317.
[4] de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure[J]. Eur Heart J, 2019, 21(3): 272-285.
[5] Atienza F, Martins RP, Jalife J. Translational research in atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2012, 5(6): 1207-1215.
[6] Nattel S, Heijman J, Zhou L, et al. Molecular basis of atrial fibrillation pathophysiology and therapy[J]. Circ Res, 2020, 127(1): 51-72.
[7] Alonso R, Mata P, Muñiz O, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia[J]. Atherosclerosis, 2016, 254: 249-253.
[8] Laugsand LE, Åsvold BO, Vatten LJ, et al. Circulating PCSK9 and risk of myocardial infarction[J]. JACC Basic Transl Sci, 2016, 1(7): 568-575.
[9] Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials[J]. Circ Res, 2018, 122(10): 1420-1438.
[10] Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains[J]. Curr Atheroscler Rep, 2015, 17(4): 499.
[11] Fitzgerald K, Simon A, White S, et al. A subcutaneously administered investigational RNAi therapeutic (ALN-PCSsc), targeting PCSK9 for the treatment of hypercholesterolemia: initial phase Ⅰ study results[C/OL]. http://www.pcsk9forum.org/wp-content/uploads/aln_pcssc_phase_ I_ data.pdf.
[12] Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden[J]. Eur Heart J, 2017, 38(32): 2499-2507.
[13] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722.
[14] Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives[J]. Eur Heart J, 2018, 39(29): 2704-2716.
[15] Ravi S, Mitchell T, Kramer P, et al. Mitochondria in monocytes and macrophages-implications for translational and basic research[J]. Int J Biochem Cell Biol, 2014, 53: 202-207.
[16] Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection[J]. Sci Signal, 2009, 2(100): ra81.
文章导航

/